-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

201. Granulocytes, Monocytes, and Macrophages: Poster III Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
Adult, Biological, Coronaviruses, HSCs, SARS-CoV-2/COVID-19, viral, bioengineering, cell division, Diseases, drug-drug interaction, cell regulation, Combinations, Elderly, Therapies, cellular interactions, Biological Processes, white blood cells, immune cells, Technology and Procedures, Cell Lineage, Infectious Diseases, Study Population, Clinically relevant, hematopoiesis, Quality Improvement , immune mechanism, inflammation, molecular testing, molecular interactions, multi-systemic interactions, signal transduction
Monday, December 7, 2020: 7:00 AM-3:30 PM

Madelaine Duarte, BA1*, Stacey A Maskarinec, MD, PhD2*, Sanjay Khandelwal, PhD3, Gowthami M. Arepally, MD1 and Grace M Lee, MD1

1Division of Hematology, Duke University Medical Center, Durham, NC
2Division of Infectious Diseases, Duke University Medical Center, Durham, NC
3Division of Hematology, Duke Medical Center, Durham, NC

Julia Skokowa, MD, PhD1,2,3,4,5, Mohammad Elgamacy, PhD, MSc, BSc6,7* and Patrick Müller6,7*

1Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology, University Hospital Tuebingen, Tuebingen, Germany
2Department of Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University Hospital Tuebingen, Tuebingen, Germany
3University Hospital Tuebingen, Tuebingen, Germany
4Medical Center II, University Hospital Tuebingen, Tuebingen, Germany
5German Cancer Research Center (DKFZ), Heidelberg, Germany
6Division of Translational Oncology, Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tuebingen, Germany
7Friedrich Miescher Laboratory of the Max Planck Society, Tuebingen, Germany

Sara L. Seegers, M.S.*, Amanda Lance, MS*, Lawrence J Druhan, PhD and Belinda R Avalos, MD

Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC

Janet Lines, PhD1*, Evelien Schaafsma, MA1*, Walburga Croteau1*, Mohamed ElTanbouly2*, Elizabeth Nowak1*, Nicole Smits3*, Cecilia Webber1*, Aurelien Sarde4*, Dina Rabadi1*, Jie Deng5*, Bruce R. Blazar, MD6, Chao Cheng7* and Randolph Noelle1*

1Geisel School of Medicine at Dartmouth, Lebanon, NH
2Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH
31Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, Lebanon
4Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, Lebanon
5Department of Radiation Oncology, UCLA, Los Angeles, CA
6Division of Pediatric Blood and Marrow Transplantation, University of Minnesota, Minneapolis, MN
7Department of Medicine, Baylor College of Medicine, Houston, TX

Jessica M Salmon, BSc PhD1*, Casie Leigh Reed, BSc1*, Maddyson Bender, BSc1*, Helen Lorraine Mitchell, BSc2*, Vanessa Fox, BSc3*, Graham William Magor, BSc1*, Matthew Sweet4* and Andrew Charles Perkins, MBBS, PhD5,6

1Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
2Australian Centre for Blood Diseases, Monash University, Melbourne, AUS
3Public Health and Preventative Medicine, Monash University, Melbourne, Australia
4Institute For Molecular Bioscience, Brisbane, AUS
5Department of Haematology, The Alfred Hospital, Melbourne, Australia
6Australian Centre for Blood Diseases, Monash University, Malvern, VIC, Australia

Jesus Romero1*, Jorge Mazzini, MD2*, Sarvari Venkata Yellapragada, MD3,4,5,6,7,8*, Iberia R. Sosa, MD, PhD9,10 and Gustavo A. Rivero, MD5,8,10,11,12,13

1Baylor St Luke’s Medical Center, Houston, Texas, 77030, Katy, TX
2Baylor St Luke’s Medical Center, Houston, Texas, 77030, Houston, TX
3Section of Hematology and Oncology, Baylor College of Medicine, Houston, TX
4Baylor College of Medicine, Houston, TX
5The Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine, Houston, TX
6Dan L Duncan Comprehensive Cancer Center, Houston, TX
7Michael E Debakey VAMC, Houston, TX
8Michael E. DeBakey VA Medical Center, Houston, TX
9Fox Chase Cancer Center, Philadelphia, PA
10Section of Hematology and Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX
11NIH-NHLBI, Houston, TX
12Dan L Duncan Comprehensive Cancer at Baylor St. Luke's Medical Center, Houston, TX
13Baylor, Houston, TX

Caroline Wilson, BS, MBBS1*, Wei-i Lee2*, Matthew Cook2,3*, Lillian Smyth3* and Dipti Talaulikar, PhD, FRACP, FRCPA, MBBS1,4

1Department of Haematology, The Canberra Hospital, Canberra, Australia
2Department of Immunology, The Canberra Hospital, Canberra, ACT, Australia
3Medical School, Australian National University, Canberra, ACT, Australia
4Medical School, The Australian National University, Canberra, Australia

Ekaterina Deordieva1*, Julia Skokowa, MD, PhD2, Anna Shcherbina3*, Galina Novichkova, MD4*, Alexey Maschan, MD4 and Karl Welte5

1Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Ministry of Healthcare of Russian Federatio, Moscow, Russia
2Department of Oncology, Hematology, Immunology, Rheumatology and Pulmonology, University Hospital Tuebingen, Tuebingen, Germany
3National Medical Research Center of Pediatric Hematology, Oncology and Immunolog, Moscow, RUS
4Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russian Federation
5The University Children's Hospital Tuebingen, Tuebingen, Germany

*signifies non-member of ASH